MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

Enterome, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has announced that the US ...

SELLAS Life Sciences Group, Inc. ( SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT ...

The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit ...

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First ...

As the biotech sector continues to evolve, breakthroughs in antibody technology are reshaping the landscape of cancer ...

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies. The FDA has granted orphan drug designation to ZEN-3694, a novel oral ...

Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most ...

Panelists discussed these questions during a recent Institute for Value-Based Medicine® event held in Nashville, Tennessee, ...